NDA 050640 · Baxter Hlthcare
Bactocill In Plastic Container
Oxacillin Sodium · Injection
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Oct 26, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
55
12 Phase 3, 5 recruiting
FAERS reports
980
917 serious, 189 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
INDICATIONS AND USAGE Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (See CLINICAL PHARMACOLOGY - Susceptibility Test Methods .) Oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Oxacillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus , therapy should not be continued with oxacillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin Injection, USP and other antibacterial drugs, Oxacillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 26, 1989 Original approval · Type 3 - New Dosage Form
2 products under this application
- BACTOCILL IN PLASTIC CONTAINER · OXACILLIN SODIUM EQ 40MG BASE/ML · INJECTABLE, INJECTION · Prescription
- BACTOCILL IN PLASTIC CONTAINER · OXACILLIN SODIUM EQ 20MG BASE/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxacillin" as an intervention, any sponsor and status, largest first.
- Determinants of Warfarin MetabolismRecruiting
Hadassah Medical OrganizationAcademic, hospital or other
NCT00162474 · 1,000 participants (planned) · Start Sep 2003 · Primary completion Dec 2030
Drug: Warfarin; Phenytoin and 4 more · For: Healthy
Sites: Jerusalem, Israel
- Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive BacteriaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00037050 · 739 participants · Start Apr 2002
Drug: Linezolid; Vancomycin and 2 more · For: Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
- Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream InfectionPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT01191840 · 509 participants · Start Feb 2011 · Primary completion Mar 4, 2017
Drug: Vancomycin; Vancomycin · For: Bacteremia
Sites: Birmingham, Alabama; Los Angeles, California; Denver, Colorado · 15 sites in all
- Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus BacteraemiaPivotal-lookingRecruiting
Region SkaneAcademic, hospital or other
NCT06726395 · 420 participants (planned) · Start Mar 10, 2025 · Primary completion Apr 2028
Drug: Penicillin G_1200mg; cloxacillin · For: Staphylococcus Aureus Bacteraemia; Staphylococcal Bacteraemia; Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) and 1 more
Sites: Lund, Sweden
- Penicillin for the Emergency Department Outpatient Treatment of CELLulitisPivotal-lookingStatus unknown
Royal College of Surgeons, IrelandAcademic, hospital or other
NCT02922686 · 414 participants (planned) · Start Dec 2016 · Primary completion Dec 2019
Drug: Flucloxacillin; Phenoxymethylpenicillin and 1 more · For: Cellulitis; Wound Infection; Abscess
Sites: Blanchardstown, Ireland; Dublin, Ireland; Cork, Ireland · 5 sites in all
- Adjunctive Clindamycin for Cellulitis: C4C Trial.Pivotal-lookingCompleted
University Hospitals Bristol and Weston NHS Foundation TrustAcademic, hospital or other
NCT01876628 · 410 participants · Start Oct 2013 · Primary completion Dec 2015
Drug: Flucloxacillin; Clindamycin and 1 more · For: Cellulitis
Sites: Bristol, United Kingdom
- Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure InfectionsPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00711802 · 396 participants · Start Jul 23, 2008 · Primary completion Oct 11, 2013
Drug: Daptomycin; Standard of Care (SOC) · For: Skin Diseases, Infectious
Sites: Birmingham, Alabama; Oakland, California; Orange, California · 30 sites in all
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective EndocarditisPivotal-lookingRecruiting
Fundacion Clinic per a la Recerca BiomédicaAcademic, hospital or other
NCT05398679 · 360 participants (planned) · Start Aug 17, 2022 · Primary completion Dec 30, 2026
Drug: Cefaclor; Ciprofloxacin Tablets and 22 more · For: Endocarditis Infective
Sites: Alicante, Spain; Seville, Spain; Palma de Mallorca, Spain · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective90
- acute kidney injury63
- drug reaction with eosinophilia and systemic symptoms54
- pyrexia49
- rash48
- drug interaction42
- off label use39
- staphylococcal infection35
- toxic epidermal necrolysis35
- pneumonia34
- renal failure33
- alanine aminotransferase increased31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 44 |
| 2005 | 27 |
| 2006 | 25 |
| 2007 | 30 |
| 2008 | 18 |
| 2009 | 30 |
| 2010 | 15 |
| 2011 | 37 |
| 2012 | 53 |
| 2013 | 16 |
| 2014 | 55 |
| 2015 | 53 |
| 2016 | 49 |
| 2017 | 57 |
| 2018 | 74 |
| 2019 | 48 |
| 2020 | 74 |
| 2021 | 59 |
| 2022 | 48 |
| 2023 | 46 |
| 2024 | 36 |
| 2025 | 47 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Prosty C, Noutsios D, Lee TC, et al. · Clin Microbiol Infect 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.
Eljaaly K, Alshehri S, Erstad BL · Antimicrob Agents Chemother 2018 · Meta-Analysis, Systematic Review
- Antimicrobial resistance of Streptococcus uberis isolated from bovine mastitis: Systematic review and meta-analysis.
Miotti C, Cicotello J, Suarez Archilla G, et al. · Res Vet Sci 2023 · Meta-Analysis, Systematic Review
- Prevalence of methicillin-resistant Staphylococcus aureus in healthy Chinese population: A system review and meta-analysis.
Wu M, Tong X, Liu S, et al. · PLoS One 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antimicrobial Susceptibility Profile of Listeria monocytogenes Isolated from Meat Products: A Systematic Review and Meta-Analysis.
Tayeb BA, Mohamed-Sharif YH, Choli FR, et al. · Foodborne Pathog Dis 2023 · Meta-Analysis, Systematic Review
- Antimicrobial resistance of Staphylococcus aureus isolated from bovine mastitis: Systematic review and meta-analysis.
Molineri AI, Camussone C, Zbrun MV, et al. · Prev Vet Med 2021 · Meta-Analysis, Systematic Review
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.